Preduprezhdenie serdechno-sosudistykhoslozhneniy u patsientov s faktorami riskas pozitsii dokazatel'noy meditsiny

Cover Page


Cite item

Full Text

Abstract

Summary. This review embraces the modern principles of cardiovascular disease prevention (CVD) as well as two
important approaches to their prevention: non-drug treatments (correction of risk factors related to lifestyle) and
drug treatments. Clinical effects and indications for use of such drug groups as antiplatelet agents, lipid-lowering
drugs, angiotensin-converting enzyme are marked. The article focuses on the treatment characteristics of patients
with multiple coronary risk factors. The results of clinical study on the antihypertensive effectiveness of Lisinopril
in patients with high-risk of hypertension and multiple risk factors are presented.

About the authors

Marina Gennad'evna Bubnova

References

  1. Оганов Р.Г., Масленникова Г.Я., Колтунов И.Е., Калинина А.М. Необходимые условия для профилактики сердечно-сосудистых и других неинфекционных заболеваний в Российской Федерации. Кардиоваск. терапия и профилактика. 2010; 9 (6): 4-9.
  2. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prevention and Rehabilitation 2007; 4 (Suppl. 2).
  3. Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в Россий- ской популяции. Кардиоваск. терапия и профилактика. 2005; 4 (1): 4-9.
  4. Fox K, Garcia MAA, Ardissino D et al Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006.
  5. Аронов Д.М., Бубнова М.Г., Перова Н.В. и др. Физические нагрузки и атеросклероз: проатерогенное влияние статических нагрузок высокой и умеренной интенсивности на липидтранс- портную систему крови. Кардиология. 2003; 2: 35-9.
  6. Бубнова М.Г., Аронов Д.М., Перова Н.В. и др. Физические нагрузки и атеросклероз: динамические физические нагрузки высокой интенсивности как фактор, индуцирующий экзогенную дислипидемию. Кардиология. 2003; 3: 43-9.
  7. Бубнова М.Г., Аронов Д.М., Перова Н.В., Зволинская Е.Ю. Физические нагрузки и атеросклероз: влияние динамических нагрузок разной интенсивности на показатели липид-транспортной системы и углеводного обмена у больных коронарной бо- лезнью сердца и сахарным диабетом 2 типа. Кардиология. 2005; 11: 33-40.
  8. Бубнова М.Г., Аронов Д.М., Оганов Р.Г. др. (от имени исследователей). Клиническая характеристика и общие подходы к лечению пациентов со стабильной стенокардией в реальной практике. Российское исследование «ПЕРСПЕКТИВА» (часть I). Кардиоваск. терапия и профилактика. 2010; 6: 47-56.
  9. Бубнова М.Г. Аспирин в профилактике атеротромбоза и коронарной болезни сердца. Рос. кардиол. журн. 2010; 4 (84): 115-21.
  10. Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients with Chronic Stable Angina. A Report of the ACC/AHA Task Force on Practice Guidelines Writing Group of Develop the Focused Update of the 2002 Guidelines for the Management of Patients with Chronic Stable Angina. Circulation 2007; 116: 2762-72.
  11. Antiplatelet Trialists`Collaboration. Collaborative overview of randomized of antiplatelet therapy: I Prevention of death, myocardial infarction, and stroke by prolonged anti-platelet in various categories of patients. BMJ 1994; 308: 81-106.
  12. Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC 2008; 51: 172-209.
  13. Calonge N, Petitti DB, DeWitt TG et al. Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2009; 150: 396-404.
  14. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Eur J Cardiovasc Prevention and Rehabilitation 2007; 4 (Suppl. 2).
  15. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1442-536.
  16. Rosendoff C, Black HR, Cannon CP et al. Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. A Scientific Statement From the American Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115: 2761-88.
  17. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-58.
  18. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiоlogy. Eur Heart J 2004, 25: 1454-70.
  19. Mancia G, Zanchetti A, Agabiti-Rosei E. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997; 95: 1464-70.
  20. Terpstra WF, May JF, Smit AJ et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertension2001; 19: 303-39.
  21. Terpstra WF, May JF, Smit AJ et al. Effect of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens 2004; 22 (7): 1309-16.
  22. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
  23. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 1997; 349: 1787-92.
  24. Funatsu H, Yamashita H, Shimizu E et al. Quantitative measurement of retinal thickness in patients with diabetic macular edema is useful for evaluation of therapeutic agents. Diabetes Res Clin Pract 2004; 66 (3): 219-27.
  25. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell`Infarto Miocardico. Lancet 1994; 343: 1115-22.
  26. Packer M, Poole-Wilson PM, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Grop. Circulation 1999; 100: 2312-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 64546 от 22.01.2016. 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies